HK1119090A1 - Coated lipid complexes and their use - Google Patents

Coated lipid complexes and their use

Info

Publication number
HK1119090A1
HK1119090A1 HK08113257.3A HK08113257A HK1119090A1 HK 1119090 A1 HK1119090 A1 HK 1119090A1 HK 08113257 A HK08113257 A HK 08113257A HK 1119090 A1 HK1119090 A1 HK 1119090A1
Authority
HK
Hong Kong
Prior art keywords
lipid complexes
coated lipid
coated
complexes
lipid
Prior art date
Application number
HK08113257.3A
Other languages
English (en)
Inventor
Oliver Keil
Joerg Kaufmann
Original Assignee
Silence Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silence Therapeutics Ag filed Critical Silence Therapeutics Ag
Publication of HK1119090A1 publication Critical patent/HK1119090A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
HK08113257.3A 2004-12-27 2008-12-05 Coated lipid complexes and their use HK1119090A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04030846 2004-12-27
PCT/EP2005/014074 WO2006069782A2 (en) 2004-12-27 2005-12-27 Lipid complexes coated with peg and their use

Publications (1)

Publication Number Publication Date
HK1119090A1 true HK1119090A1 (en) 2009-02-27

Family

ID=36540272

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08113257.3A HK1119090A1 (en) 2004-12-27 2008-12-05 Coated lipid complexes and their use
HK16110655.7A HK1222541A1 (zh) 2004-12-27 2016-09-07 塗層脂質複合體和它們的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16110655.7A HK1222541A1 (zh) 2004-12-27 2016-09-07 塗層脂質複合體和它們的用途

Country Status (17)

Country Link
US (2) US8852472B2 (xx)
EP (2) EP2992902A1 (xx)
JP (1) JP5292572B2 (xx)
KR (1) KR101366482B1 (xx)
CN (1) CN101287497B (xx)
AU (1) AU2005321469B2 (xx)
BR (1) BRPI0519468A2 (xx)
CA (1) CA2593032C (xx)
DK (1) DK1830888T3 (xx)
ES (1) ES2548515T3 (xx)
HK (2) HK1119090A1 (xx)
IL (1) IL183775A (xx)
MX (1) MX2007007913A (xx)
PL (1) PL1830888T3 (xx)
SG (1) SG158175A1 (xx)
WO (1) WO2006069782A2 (xx)
ZA (1) ZA200704168B (xx)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
CN1968714B (zh) 2004-05-05 2013-10-16 赛伦斯治疗公司 脂质、脂质复合物及其应用
KR101366482B1 (ko) 2004-12-27 2014-02-21 사일런스 테라퓨틱스 아게 코팅된 지질 복합체 및 이들의 용도
KR101418369B1 (ko) * 2005-05-04 2014-07-24 녹손 파르마 아게 스피에겔머들의 신규 용도
AU2007241370A1 (en) * 2006-04-20 2007-11-01 Silence Therapeutics Ag. Lipoplex formulations for specific delivery to vascular endothelium
CA2658550C (en) * 2006-07-21 2018-06-19 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
US8193246B2 (en) 2006-12-19 2012-06-05 Marina Biotech, Inc. Lipids and lipid assemblies comprising transfection enhancer elements
EP2326351B1 (en) 2008-08-19 2017-12-27 Nektar Therapeutics Conjugates of small-interfering nucleic acids
WO2010094491A1 (en) 2009-02-18 2010-08-26 Silence Therapeutics Ag Means for inhibiting the expression of ang2
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
US8359883B2 (en) * 2009-11-13 2013-01-29 Hasmukh Dholakiya Gemstone setting
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
WO2012113413A1 (en) * 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
TW201726599A (zh) 2012-07-06 2017-08-01 協和醱酵麒麟有限公司 陽離子性脂質
WO2014018375A1 (en) 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
JP6896421B2 (ja) 2013-08-21 2021-06-30 キュアバック アーゲー 呼吸器合胞体ウイルス（ｒｓｖ）ワクチン
KR20160095003A (ko) * 2013-12-05 2016-08-10 사일런스 테라퓨틱스 게엠베하 폐 특이적 전달을 위한 수단
US10611664B2 (en) 2014-07-31 2020-04-07 Corning Incorporated Thermally strengthened architectural glass and related systems and methods
US11097974B2 (en) 2014-07-31 2021-08-24 Corning Incorporated Thermally strengthened consumer electronic glass and related systems and methods
WO2016083623A1 (en) * 2014-11-28 2016-06-02 Silence Therapeutics Gmbh Means for the treatment of pre-eclampsia
WO2017123573A2 (en) 2016-01-12 2017-07-20 Corning Incorporated Thin thermally and chemically strengthened glass-based articles
US11795102B2 (en) 2016-01-26 2023-10-24 Corning Incorporated Non-contact coated glass and related coating system and method
CN105902523A (zh) * 2016-03-14 2016-08-31 苏州博创康源生物技术有限公司 一种载药组织粘贴膜及其制备方法
CN106038517A (zh) * 2016-03-14 2016-10-26 苏州博创康源生物技术有限公司 一种多糖药物载药组织粘贴膜及其制备方法
CN105832709A (zh) * 2016-03-14 2016-08-10 苏州博创康源生物技术有限公司 一种核酸药物载药组织粘贴膜及其制备方法
CN105687165A (zh) * 2016-03-14 2016-06-22 苏州博创康源生物技术有限公司 一种蛋白或多肽药物载药组织粘贴膜及其制备方法
CN106038516A (zh) * 2016-03-14 2016-10-26 苏州博创康源生物技术有限公司 一种化合物药物载药组织粘贴膜及其制备方法
EP3500670B1 (en) 2016-08-17 2024-07-10 The Broad Institute, Inc. Method for selecting target sequences for guide rna of crispr systems
CN110114461A (zh) 2016-08-17 2019-08-09 博德研究所 新型crispr酶和***
TW201920028A (zh) 2017-08-24 2019-06-01 美商康寧公司 具有改良回火能力之玻璃
KR102338449B1 (ko) 2017-09-21 2021-12-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
US12018080B2 (en) 2017-11-13 2024-06-25 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
TWI785156B (zh) 2017-11-30 2022-12-01 美商康寧公司 具有高熱膨脹係數及對於熱回火之優先破裂行為的非離子交換玻璃
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
AU2019318079A1 (en) 2018-08-07 2021-01-28 Massachusetts Institute Of Technology Novel Cas12b enzymes and systems
WO2020191102A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Type vii crispr proteins and systems
US20220220469A1 (en) 2019-05-20 2022-07-14 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
JP2022542839A (ja) 2019-07-19 2022-10-07 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー リコンビナーゼ組成物及び使用方法
CN114514115B (zh) 2019-08-06 2023-09-01 康宁股份有限公司 具有用于阻止裂纹的埋入式应力尖峰的玻璃层压体及其制造方法
WO2021195218A1 (en) 2020-03-24 2021-09-30 Generation Bio Co. Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
MX2022011805A (es) 2020-03-24 2023-01-11 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix.
EP4153224A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Coronavirus antigen compositions and their uses
EP4153223A1 (en) 2020-05-20 2023-03-29 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
AU2021281453A1 (en) 2020-05-29 2022-11-17 Flagship Pioneering Innovations Vi, Llc. Trem compositions and methods relating thereto
EP4158031A1 (en) 2020-05-29 2023-04-05 Flagship Pioneering Innovations VI, LLC Trem compositions and methods relating thereto
US20230272432A1 (en) 2020-07-27 2023-08-31 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
AU2021336976A1 (en) 2020-09-03 2023-03-23 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and uses thereof
BR112023012377A2 (pt) 2020-12-23 2023-10-24 Flagship Pioneering Innovations Vi Llc Composições de trems modificadas e usos das mesmas
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CA3214538A1 (en) 2021-04-20 2022-10-27 Joel DE BEER Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
IL308404A (en) 2021-04-27 2024-01-01 Generation Bio Co Non-viral DNA vectors expressing therapeutic antibodies and uses thereof
US20240216535A1 (en) 2021-04-27 2024-07-04 Generation Bio Co. Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
CN113372226B (zh) * 2021-06-08 2023-05-26 深圳市人民医院 一种脂质分子、脂质纳米粒及其制备方法和应用
EP4377457A1 (en) 2021-07-26 2024-06-05 Flagship Pioneering Innovations VI, LLC Trem compositions and uses thereof
AR127073A1 (es) 2021-09-17 2023-12-13 Flagship Pioneering Innovations Vi Llc Composiciones y métodos para producir polirribonucleótidos circulares
WO2023069397A1 (en) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
IL312490A (en) 2021-11-08 2024-07-01 Orna Therapeutics Inc Fat nanoparticle preparations for the administration of circular polynucleotides
AU2022397300A1 (en) 2021-11-24 2024-06-27 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
WO2023096990A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
IL312799A (en) 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions of varicella-zoster virus and uses thereof
CA3240691A1 (en) 2021-12-17 2023-06-22 Alexandra Sophie DE BOER Methods for enrichment of circular rna under denaturing conditions
TW202340461A (zh) 2021-12-22 2023-10-16 美商旗艦先鋒創新有限責任公司 用於純化多核糖核苷酸之組成物和方法
WO2023122789A1 (en) 2021-12-23 2023-06-29 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2023135273A2 (en) 2022-01-14 2023-07-20 Anjarium Biosciences Ag Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023183616A1 (en) 2022-03-25 2023-09-28 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023220083A1 (en) 2022-05-09 2023-11-16 Flagship Pioneering Innovations Vi, Llc Trem compositions and methods of use for treating proliferative disorders
TW202409283A (zh) 2022-05-13 2024-03-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 雙股ｄｎａ組合物及相關方法
WO2023239756A1 (en) 2022-06-07 2023-12-14 Generation Bio Co. Lipid nanoparticle compositions and uses thereof
WO2023250112A1 (en) 2022-06-22 2023-12-28 Flagship Pioneering Innovations Vi, Llc Compositions of modified trems and uses thereof
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024035952A1 (en) 2022-08-12 2024-02-15 Remix Therapeutics Inc. Methods and compositions for modulating splicing at alternative splice sites
WO2024040222A1 (en) 2022-08-19 2024-02-22 Generation Bio Co. Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024049979A2 (en) 2022-08-31 2024-03-07 Senda Biosciences, Inc. Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024097664A1 (en) 2022-10-31 2024-05-10 Flagship Pioneering Innovations Vi, Llc Compositions and methods for purifying polyribonucleotides
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102677A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Circular rna compositions
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024102799A1 (en) 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
WO2024119074A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Stealth lipid nanoparticle compositions for cell targeting
WO2024119103A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
WO2024119051A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
WO2024119039A2 (en) 2022-12-01 2024-06-06 Generation Bio Co. Stealth lipid nanoparticles and uses thereof
WO2024129988A1 (en) 2022-12-14 2024-06-20 Flagship Pioneering Innovations Vii, Llc Compositions and methods for delivery of therapeutic agents to bone
US20240238473A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
WO2024151685A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1493825A3 (en) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Method for producing nucleic acid ligands
GB2270920B (en) 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
FR2698628B1 (fr) 1992-12-02 1995-02-17 Fournier Ind & Sante Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5777153A (en) 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
IL122290A0 (en) 1995-06-07 1998-04-05 Inex Pharmaceuticals Corp Lipid-nucleic acid complex its preparation and use
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
WO1997003939A1 (en) 1995-07-21 1997-02-06 Genta Incorporated Novel amide-based cationic lipids
AU743469C (en) 1996-08-30 2004-02-12 Rolf Bald Mirror-symmetrical selection and evolution of nucleic acids
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6958239B2 (en) 1996-11-21 2005-10-25 Oligos Etc Inc. Three component chimeric antisense oligonucleotides
CA2217550A1 (en) 1996-10-22 1998-04-22 F. Hoffmann-La Roche Ag Cationic lipids for gene therapy
US6358523B1 (en) 1996-12-06 2002-03-19 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and regulating
WO1998044909A1 (en) 1997-04-04 1998-10-15 Valentis Inc. Improved methods of delivery using cationic lipids and helper lipids
AU7490098A (en) 1997-05-15 1998-12-08 Genzyme Corporation Cationic amphiphile formulations
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
US20030073640A1 (en) * 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
WO1999004819A1 (en) * 1997-07-24 1999-02-04 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US6150345A (en) 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
FR2788275B1 (fr) 1999-01-11 2002-06-14 Lipha ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7015040B2 (en) * 1999-02-26 2006-03-21 Mirus Bio Corporation Intravascular delivery of nucleic acid
WO2000073469A2 (en) 1999-05-28 2000-12-07 Sugen, Inc. Protein kinases
EP1064944A1 (en) 1999-06-25 2001-01-03 Schering Aktiengesellschaft Protein kinase N inhibitor comprising Fasudil
DE60017406T2 (de) 1999-07-15 2005-09-29 Inex Pharmaceuticals Corp., Burnaby Verfahren zur herstellung von in lipid verkapselten therapeutischen wirkstoffen
US6133032A (en) 1999-09-09 2000-10-17 Isis Pharmaceutical Inc. Antisense modulation of PI3 kinase p110 beta expression
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
CA2403962C (en) 2000-03-31 2009-12-15 Kirin Beer Kabushiki Kaisha Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability
JP2004508012A (ja) * 2000-04-20 2004-03-18 ザ　ユニバーシティ　オブ　ブリティッシュ　コロンビア エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法
CA2426244A1 (en) * 2000-10-25 2002-05-02 The University Of British Columbia Lipid formulations for target delivery
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
US20030135033A1 (en) 2002-01-04 2003-07-17 Anke Klippel-Giese Compounds and methods for the identification and/ or validation of a target
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
AU2003258075A1 (en) 2002-08-06 2004-02-23 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
EP1393742A1 (en) 2002-08-14 2004-03-03 atugen AG Use of protein kinase N beta
CA2495072A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
AU2003299818A1 (en) 2002-12-20 2004-07-22 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7196145B2 (en) * 2003-08-26 2007-03-27 Smithkline Beecham Corporation Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions
CN1968714B (zh) 2004-05-05 2013-10-16 赛伦斯治疗公司 脂质、脂质复合物及其应用
KR20070085232A (ko) 2004-08-20 2007-08-27 더 존스 홉킨스 유니버시티 혈관신생 치료방법
AU2005306075A1 (en) 2004-11-19 2006-05-26 Novosom Ag Improvements in or relating to pharmaceutical compositions for local administration
KR101366482B1 (ko) 2004-12-27 2014-02-21 사일런스 테라퓨틱스 아게 코팅된 지질 복합체 및 이들의 용도
WO2006074546A1 (en) 2005-01-13 2006-07-20 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
KR20090004984A (ko) 2006-04-20 2009-01-12 사일런스 테라퓨틱스 아게 Ｃｄ31의 발현을 억제하기 위한 수단
AU2007241370A1 (en) 2006-04-20 2007-11-01 Silence Therapeutics Ag. Lipoplex formulations for specific delivery to vascular endothelium
CA2658550C (en) 2006-07-21 2018-06-19 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3

Also Published As

Publication number Publication date
AU2005321469A1 (en) 2006-07-06
ES2548515T3 (es) 2015-10-19
CN101287497A (zh) 2008-10-15
HK1222541A1 (zh) 2017-07-07
BRPI0519468A2 (pt) 2009-01-27
US20150031752A1 (en) 2015-01-29
SG158175A1 (en) 2010-01-29
EP2992902A1 (en) 2016-03-09
EP1830888B1 (en) 2015-08-05
US8852472B2 (en) 2014-10-07
JP5292572B2 (ja) 2013-09-18
KR20070090956A (ko) 2007-09-06
WO2006069782A3 (en) 2007-04-12
ZA200704168B (en) 2008-05-28
US9387262B2 (en) 2016-07-12
WO2006069782A9 (en) 2009-04-30
CA2593032C (en) 2015-12-22
WO2006069782A2 (en) 2006-07-06
JP2008525514A (ja) 2008-07-17
IL183775A0 (en) 2007-09-20
CN101287497B (zh) 2013-03-06
DK1830888T3 (en) 2015-10-19
IL183775A (en) 2016-12-29
EP1830888A2 (en) 2007-09-12
MX2007007913A (es) 2007-08-14
AU2005321469B2 (en) 2012-04-05
CA2593032A1 (en) 2006-07-06
KR101366482B1 (ko) 2014-02-21
PL1830888T3 (pl) 2015-12-31
US20100062967A1 (en) 2010-03-11

Similar Documents

Publication Publication Date Title
HK1119090A1 (en) Coated lipid complexes and their use
IL178879A0 (en) Lipids, lipid complexes and use thereof
EP1731506A4 (en) 5-HYDROXYINDOL-3-CARBOXYLATE DERIVATIVES AND THEIR USE
IL218117A (en) A tablet containing saxagliptin and several layers of coating
HK1101911A1 (en) Tetrahydrocarbozoles and derivatives
IL181670A0 (en) Substituted phenylaminothiazoles and use thereof
EP1814841A4 (en) CERAMIDES AND LIGANDS OF SIGNALING APOPTOSIS
IL178888A0 (en) Arylphenylamino-, arylphenylamide-, and arylphenylether-sulfide derivatives
IL189252A0 (en) Dihydroxyanthraquinones and their use
EP1786415A4 (en) METABOLISM MODULATION AGENTS AND USES THEREOF
EP1810976A4 (en) BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND THE USE THEREOF
GB0426903D0 (en) Complexes and methods
GB0700332D0 (en) Dispenser and components thereof
EP1816136A4 (en) GPR7 SELECTIVE LIGAND AND APPLICATION THEREOF
EP1736544A4 (en) GM1 PROMOTER AND ITS USE
GB0427723D0 (en) Compounds and their use
GB0515322D0 (en) Ligands and use thereof
HU0400218V0 (en) Coated curd-dessert
GB0410832D0 (en) Compounds and their use
GB0402903D0 (en) Compounds and their use
GB0411071D0 (en) Compounds and their use
GB0416630D0 (en) Compounds and their use
GB0423234D0 (en) Compounds and their use
GB0405304D0 (en) Compounds and their use
GB0403953D0 (en) Compounds and their use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161227